YAP1 and hepatocellular carcinoma: To dissect the genetic casualty of HCC initiation and progression, and to identify potential therapeutic target for HCC treatment, we employed a mosaic HCC mouse model and identified Yes-associated protein (YAP) as a bona-fide oncogene in liver cancer [5, 6].